James Patton, MD
Neurology · Asheville, NCNPI 1518945690
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $94,975 of the $136,146 with a category attached, or 69.8%. 60 manufacturers reported payments, led by AbbVie at 25.9% of the total. Reporting peaked in 2019 at $68,382 and has fallen 96.3% since, to $2,534 in 2025. Among neurology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,013 payments — averaging $134.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$35K
- Biogen$30K
- EMD Serono, Inc.$24K
- Acorda Therapeutics, Inc$18K
- Kyowa Kirin, Inc.$10K
- Sanofi$7K
- plus $12K from 54 others
Across 50 payments — averaging $11,227 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$497K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$28K
- Bristol Myers Squibb$23K
- AbbVie$11K
- E.r. Squibb & Sons, L.L.C.$2K
- Jazz Pharmaceuticals Inc.$210
What the payments were for
- Consulting fees$13,26210%
- Speaking & faculty fees$94,97570%
- Travel & lodging$8,6706%
- Food & beverage$18,98114%
- Education$2580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$136,146 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 46 | $276,008 |
| BotoxOnabotulinumtoxina | 175 | $229,661 |
| TysabriNatalizumab | 15 | $141,830 |
| RytaryCarbidopa/Levodopa | 65 | $91,723 |
| UbrelvyUbrogepant | 45 | $57,018 |
| Nurtec OdtRimegepant Sulfate | 37 | $53,504 |
| XeominIncobotulinumtoxina | 43 | $40,677 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 922 | $30,303 |
| GablofenBaclofen | 21 | $21,156 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $14,123 |
| MyrbetriqMirabegron | 19 | $13,542 |
| LyricaPregabalin | 15 | $12,390 |
| Topiramate ErTopiramate | 14 | $11,754 |
| Gabapentin | 483 | $9,667 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 153 | $9,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy | $35,329 | $286,678220 claims |
| Acadia Pharmaceuticals IncNuplazid | $396 | $276,00846 claims |
| BiogenTysabri | $29,658 | $141,83015 claims |
| Amneal Pharmaceuticals LLCRytary | $271 | $91,72365 claims |
| PfizerNurtec Odt, Lyrica | $265 | $65,89352 claims |
| Upsher-smith Laboratories LLCTopiramate | $90 | $1,365135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 566 neurology providers in North Carolina.
Other neurology in Asheville
- Robert ArmstrongAsheville$53K
- Jill ConwayCharlotte$1M
- Matthew CarraroCharlotte$695K
- Richard SaterGreensboro$682K
- Sara SaccoMatthews$651K
- Megan DonnellyCharlotte$601K
- Kevin KahnDurham$587K
- Sanjay IyerCharlotte$581K
- Mark SkeenDurham$562K
- Douglas JefferyMooresville$486K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.